Skip to main content
SpringerLink
Log in

5-HT1A Partial Agonists

What is Their Future?

  • Leading Article
  • Published:
Drugs Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  • Amsterdam JD, Berwish N, Potter L, Rickeis K. Open trial of gepirone in the treatment of major depressive disorder. Current Theory and Research 41 (Suppl. 2): 185–193, 1987

    Google Scholar 

  • Ananth J, Peckhold JC, vandenSteen N, Englesmann F. Double-blind comparative study of clomipramine and amitriptyline in obsessive neurosis. Progress in Neuropsychopharmacology and Biological Psychiatry 5: 257–262, 1981

    CAS  Google Scholar 

  • Aprison MH, Hingten JN. Serotonin and behavior: a brief summary. Federation Proceedings 31: 121–129, 1972

    PubMed  CAS  Google Scholar 

  • Arora RC, Meltzer HY. Serotonergic measures in the brains of suicide victims: 5-HT2 binding sites in the frontal cortex of suicide victims and control subjects. American Journal of Psychiatry 146(6): 730–736, 1989

    PubMed  CAS  Google Scholar 

  • Asberg M, Nordstrom P, Traskman-Bendz L. Cerebrospinal fluid in suicide: an overview. Annals of the New York Academy of Sciences 487: 243–255, 1986

    Article  PubMed  CAS  Google Scholar 

  • Asberg M, Traskman L, Thoren P. 5-HIAA in the cerebrospinal fluid: a biochemical suicide predictor? Archives of General Psychiatry 33: 1193, 1976

    Article  PubMed  CAS  Google Scholar 

  • Balon R. Buspirone for attention deficit hyperactivity disorders. Journal of Clinical Psychopharmacology 10(1): 77, 1990

    Article  PubMed  CAS  Google Scholar 

  • Balster RL. Abuse potential of buspirone and related drugs. Journal of Clinical Psychopharmacology 10 (Suppl.): 31S–37S, 1990

    Article  PubMed  CAS  Google Scholar 

  • Benkelfat C, Murphy DL, Zohar J, Hill JL, Grover G, et al. Clomipramine in obsessive-compulsive disorder: further evidence for a serotonergic mechanism of action. Archives of General Psychiatry 46: 23–28, 1989

    Article  PubMed  CAS  Google Scholar 

  • Blier P, de Montigny C. Modification of 5-HT neuron properties by sustained administration of the 5-HT1A agonist gepirone: electrophysiological studies in the rat brain. Synapse 1: 470–480, 1987

    Article  PubMed  CAS  Google Scholar 

  • Böhm C, Placchi M, Stallone F, Gammans RE, Alms DR, et al. A double-blind comparison of buspirone, clobazam, and placebo in patients with anxiety treated in a general practice setting. Journal of Clinical Psychopharmacology 10 (Suppl.): 38S–42S, 1990

    Article  PubMed  Google Scholar 

  • Brody JF. Behavioral effects of serotonin depletion and of p-chlorophenylalanine (a serotonin depletor) in rats. Psychopharmacologia 17: 14–33, 1970

    Article  PubMed  CAS  Google Scholar 

  • Brown GL, Goodwin FK. Cerebrospinal fluid correlates of suicide attempts and aggression. Annals of the New York Academy of Sciences 487: 175–188, 1986

    Article  PubMed  CAS  Google Scholar 

  • Bruno F. Buspirone in the treatment of alcoholic patients. Psychopathology 22 (Suppl. 1): 49–59, 1989

    Article  PubMed  Google Scholar 

  • Cervo L, Samanin R. Potential antidepressant properties of 8-hydroxy-2-(di-n-propylamino) tetralin, a selective serotonin 1A receptor agonist. European Journal of Pharmacology 144: 223–229, 1987

    Article  PubMed  CAS  Google Scholar 

  • Charney DS, Redmond Jr DE. Neurobiological mechanisms in human anxiety: evidence supporting central noradrenergic hyperactivity. Neuropharmacology 22: 1531–1536, 1983

    Article  PubMed  CAS  Google Scholar 

  • Chignon JM, Lepine JP. Panic and hypertension associated with single dose of buspirone. Lancet 2(8653): 46–47, 1989

    Article  PubMed  CAS  Google Scholar 

  • Coccaro EF, Siever LJ, Klar HM, Maurer G, Cochrane K, et al. Serotonergic studies in patients with affective and personality disorders: correlates with suicidal and impulsive aggressive behavior. Archives of General Psychiatry 46(7): 587–599, 1989

    Article  PubMed  CAS  Google Scholar 

  • Cole JO, Orzack MH, Beake B. Assessment of the abuse liability of buspirone in recreational sedative users. Journal of Clinical Psychiatry 43: 69–74, 1982

    PubMed  CAS  Google Scholar 

  • Collins DM, Myers RD. Buspirone attenuates volitional alcohol intake in the chronically drinking monkey. Alcohol 4: 49–56, 1987

    Article  PubMed  CAS  Google Scholar 

  • Cott JM, Kurtz NM, Robinson DS, Lancaster SP, Copp JE. A 5-HT1A ligand with both antidepressant and anxiolytic properties. Psychopharmacology Bulletin 24(1): 164–167, 1988

    PubMed  CAS  Google Scholar 

  • Craft RM, Howard JL, Pollard GT. Conditioned defensive burying as a model for identifying anxiolytics. Pharmacology, Biochemistry and Behavior 30(3): 775–780, 1988

    Article  CAS  Google Scholar 

  • Csanalosi I, Schweizer E, Case WG, Rickeis K. Gepirone in anxiety: a pilot study. Journal of Clinical Psychopharmacology 7(1): 31–33, 1987

    Article  PubMed  CAS  Google Scholar 

  • Curzon G. 5-Hydroxytryptamine and corticosterone in an animal model of depression. Progress in Neuropsychopharmacology and Biological Psychiatry 13: 3–4, 1989

    Article  Google Scholar 

  • Deakin JFW. 5HT2 receptors, depression and anxiety. Pharmacology, Biochemistry and Behavior 29: 819–820, 1988

    Article  CAS  Google Scholar 

  • Den Boer JA, Westenberg HGM. Effect of a serotonin and noradrenaline uptake inhibitor in panic disorder: a double-blind comparative study with fluvoxamine and maprotiline. International Clinical Psychopharmacology 3: 59–74, 1988

    Article  Google Scholar 

  • Den Boer JA, Westenberg HGM, Kamerbeek WDJ, Ferhoeven WM. Effect of serotonin uptake inhibitors in anxiety disorders: a double-blind comparison of clomipramine and fluvoxamine. International Clinical Psychopharmacology 2: 21–32, 1987

    Article  Google Scholar 

  • Dourish CT, Hutson PH, Curzon G. Putative anxiolytics 8-OH-DPAT, buspirone and TVX Q 7821 are agonists at 5-HT 1A autoreceptors in the raphe nuclei. Trends in Pharmacological Sciences 7: 212–214, 1986

    Article  CAS  Google Scholar 

  • Eichelman B. Neurochemical basis of aggressive behavior. Psychiatry Annals 17: 371–374, 1987

    Google Scholar 

  • Eison AS, Eison MS, Stanley M, Riblet LA. Serotonergic mechanisms in the behavioral effects of buspirone and gepirone. Pharmacology, Biochemistry and Behavior 24: 701–707, 1986

    Article  CAS  Google Scholar 

  • Eison AS, Yocca FD. Reduction in cortical 5HT2 receptor sensitivity after continuous gepirone treatment. European Journal of Pharmacology 111: 389–392, 1985

    Article  PubMed  CAS  Google Scholar 

  • Engel JA, Hjorth S, Svensson K, Carlsson A, Lijequist S. Anti-conflict effect of the putative serotonin receptor agonist 8-hydroxy-2-(di-n-propylamino) tetralin (8-OH-DPAT). European Journal of Pharmacology 105: 365–368, 1984

    Article  PubMed  CAS  Google Scholar 

  • Eriksson E, Humble M. Serotonin in psychiatric pathophysiology: a review of data from experimental and clinical research. In Pohl R & Gershon S (Eds) Progress in basic and clinical pharmacology: biological basis of psychiatric treatment, pp. 66–119, Karger AG, Basel, 1990

    Google Scholar 

  • Feighner JP, Cohn JB. Analysis of individual symptoms in generalized anxiety: a pooled, multistudy, double-blind evaluation of buspirone. Neuropsychobiology 21: 124–130, 1989

    Article  PubMed  CAS  Google Scholar 

  • Feighner JP, Merideth CH, Hendrickson GA. A double-blind comparison of buspirone and diazepam in outpatients with generalized anxiety disorder. Journal of Clinical Psychiatry 43(12): 103–107, 1982

    PubMed  CAS  Google Scholar 

  • Fontaine R, Chouinard G. An open clinical trial of fluoxetine in the treatment of obsessive compulsive disorder. Journal of Clinical Psychopharmacology 6: 98–101, 1986

    Article  PubMed  CAS  Google Scholar 

  • Geller I, Blum K. The effects of 5-HTP on para-chlorophenylalanine (p-CPA) attentuation of ‘conflict’ behavior. European Journal of Pharmacology 9: 319–324, 1970

    Article  PubMed  CAS  Google Scholar 

  • Geller I, Hartman RJ. Effects of buspirone on operant behavior of laboratory rats and cynomologus monkeys. Journal of Clinicl Psychiatry 43(12): 25, 1982

    CAS  Google Scholar 

  • Giral P, Martin P, Soubrié P, Simon P. Reversal of helpless behavior in rats by putative 5-HT1A agonists. Biological Psychiatry 23: 237–242, 1988

    Article  PubMed  CAS  Google Scholar 

  • Glaser T. Ipsapirone, a potent and selective 5-HT1A-receptor ligand with anxiolytic and antidepressant properties. Drugs of the Future 13: 429–439, 1988

    Google Scholar 

  • Goa KL, Ward A. Buspirone: a preliminary review of its pharmacological properties and therapeutic efficacy as an anxiolytic. Drugs 32: 114–129, 1986

    Article  PubMed  CAS  Google Scholar 

  • Goldberg HL, Finnerty R. The comparative efficacy of buspirone and diazepam in the treatment of anxiety. American Journal of Psychiatry 136(9): 1184–1187, 1979

    PubMed  CAS  Google Scholar 

  • Goldberg HL, Finnerty R. Comparison of buspirone in two separate studies. Journal of Clinical Psychiatry 32(12): 87–91, 1982

    Google Scholar 

  • Goodman WK, Price LH, Rasmussen SA, Delgado PL, Heninger GR, et al. Efficacy of fluvoxamine in obsessive-compulsive disorder: a double-blind comparison with placebo. Archives of General Psychiatry 46: 36–44, 1989

    Article  PubMed  CAS  Google Scholar 

  • Gorelik DA. Effect of fluoxetine on alcohol consumption. Alcoholism (NY) 10: 113, 1986

    Google Scholar 

  • Gower AJ, Tricklebank MD. Alpha-2-adrenoceptor antagonist activity may account for the effects of buspirone in an anticonflict test in the rat. European Journal of Pharmacology 155: 129–137, 1988

    Article  PubMed  CAS  Google Scholar 

  • Harto NE, Branconnier RJ, Spera KF, Dessain EC. Clinical profile of gepirone, a nonbenzodiazepine anxiolytic. Psychopharmacology Bulletin 24(1): 154–160, 1988

    PubMed  CAS  Google Scholar 

  • Higgins GA, Bradbury AJ, Jones BJ, Oakley NR. Behavioural and biochemical consequences following activation of 5HT1-like and GABA receptors in the dorsal raphe nucleus of the rat. Neuropharmacology 27(10): 993–1001, 1988

    Article  PubMed  CAS  Google Scholar 

  • Hjorth S, Carlsson A. Buspirone effects on central monoaminergic transmission: possible relevance to animal experimental and clinical findings. European Journal of Pharmacology 83: 299–303, 1982

    Article  PubMed  CAS  Google Scholar 

  • Hoes MJAJM, Colla P, Folgering H. Hyperventilation syndrome, treatment with L-tryptophan and pyridoxine; predictive values of xanthurenic acid excretion. Journal of Orthomolecular Psychiatry 10: 7–15, 1981

    Google Scholar 

  • Insel TR, Murphy DL, Cohen RM, Alterman I, Kilts C, et al. Obsessive-compulsive disorder: a double-blind trial of clomipramine and clorgyline. Archives of General Psychiatry 40: 605–612, 1983

    Article  PubMed  CAS  Google Scholar 

  • Jenike MA, Baer L. An open trial of buspirone in obsessive-compulsive disorder. American Journal of Psychiatry 145(10): 1285–1286, 1988

    PubMed  CAS  Google Scholar 

  • Jenkins SW, Robinson DS, Fabre LF, Andary JJ, Messina ME, et al. Gepirone in the treatment of major depression. Journal of Clinical Psychopharmacology 10 (Suppl.): 77S–85S, 1990

    Article  PubMed  CAS  Google Scholar 

  • Johnston AL, File SE. 5-HT and anxiety: promises and pitfalls. Pharmacology, Biochemistry and Behavior 24: 1467–1470, 1986

    Article  CAS  Google Scholar 

  • Kahn RS, Westenberg HGM. L-5-hydroxytryptophan in the treatment of anxiety disorders. Journal of Affective Disorders 8: 197–200, 1985

    Article  PubMed  CAS  Google Scholar 

  • Kahn RS, Westenberg HGM, Verhoeven WMA, Gispen-de Wied CC, Kamerbeck WD. Effect of a serotonin precursor and uptake inhibitor in anxiety disorders: a double-blind comparison of 5-hydroxytryptophan, clomipramine and placebo. International Clinical Psychopharmacology 2: 21–32, 1987

    Article  PubMed  Google Scholar 

  • Kennett GA, Dourish CT, Curzon G. Antidepressant-like action of 5-HT1A agonists and conventional antidepressants in an animal model of depression. European Journal of Pharmacology 134: 265–272, 1987a

    Article  PubMed  CAS  Google Scholar 

  • Kennett GA, Marcou M, Dourish CT, Curzon G. Single administration of 5-HT1A agonists decreases 5-HT1A presynaptic, but not postsynaptic receptor-medicated responses: relationship to antidepressant-like action. European Journal of Pharmacology 138: 53–60, 1987b

    Article  PubMed  CAS  Google Scholar 

  • Kranzler HR, Meyer RE. An open trial of buspirone in alcoholics. Journal of Clinical Psychopharmacology 9(5): 379–380, 1989

    Article  PubMed  CAS  Google Scholar 

  • Lader M. Psychological effects of buspirone. Journal of Clinical Psychiatry 43: 62–67, 1982

    PubMed  CAS  Google Scholar 

  • Legghio NE, Yeragani VK. Buspirone-induced hypomania: a case report. Journal of Clinical Psychopharmacology 8(3): 226–227, 1988

    Article  Google Scholar 

  • Lidberg L, Tuck JR, Asberg M, Scalia-Tomba GP, Bertilsson L. Homicide, suicide and CSF 5-HIAA. Acta Psychiatrica Scandinavica 71: 230–236, 1985

    Article  PubMed  CAS  Google Scholar 

  • Linnoila M, Virkkunen M, Scheinin M, Nuutila A, Rimon R, et al. Low cerebrospinal fluid 5-hydroxyindoleacetic acid concentration differentiates impulsive from nonimpulsive violent behavior. Life Sciences 33: 2609–2614, 1983

    Article  PubMed  CAS  Google Scholar 

  • Markovitz PJ, Stagno SJ, Calabrese JR. Buspirone augmentation of fluoxetine in obsessive-compulsive disorder. American Journal of Psychiatry 147(6): 798–800, 1990

    PubMed  CAS  Google Scholar 

  • Martin KF, Mason R. Ipsapirone is a partial agonist at 5-hydroxytryptamine 1A (5-HT 1A) receptors in the rat hippocampus: electrophysiological evidence. European Journal of Pharmacology 141: 479–483, 1987

    Article  PubMed  CAS  Google Scholar 

  • McDaniel JS, Ninan PT, Magnuson JV. Possible induction of mania by buspirone. American Journal of Psychiatry 147(1): 125–126, 1990

    PubMed  CAS  Google Scholar 

  • McMillen BA, Scott SM, Williams HL, Sanghera MK. Effects of gepirone, an aryl-piperazine anxiolytic drug, on aggressive behavior and brain monoaminergic neurotransmission. Archiv der Pharmazie 335: 454–464, 1987

    Article  CAS  Google Scholar 

  • McTavish D, Benfield P. Clomipramine: an overview of its pharmacological properties and a review of its therapeutic use in obsessive compulsive disorder and panic disorder. Drugs 39: 136–153, 1990

    Article  PubMed  CAS  Google Scholar 

  • Mendels J, Frazer A. Brain biogenic amine depletion and mood. Archives of General Psychiatry 30: 447–451, 1974

    Article  PubMed  CAS  Google Scholar 

  • Morand C, Young SN, Ervin FR. Clinical response of aggressive schizophrenics to oral tryptophan. Biological Psychiatry 18: 575–578, 1983

    PubMed  CAS  Google Scholar 

  • Morgane PJ, Jacobs MS. Raphe projections to the locus coeruleus in the rat. Brain Research Bulletin 4: 519–534, 1979

    Article  PubMed  CAS  Google Scholar 

  • Moshowitz H, Smiley A. Effects of chronically administered buspirone and diazepam on driving-related skills performance. Journal of Clinical Psychiatry 43: 45–55, 1982

    Google Scholar 

  • Moss HB. Serotonergic activity and disinhibitory psychopathy in alcoholism. Medical Hypotheses 23: 353–361, 1987

    Article  PubMed  CAS  Google Scholar 

  • Murphy SM, Owen R, Tyrer P. Comparative assessment of efficacy and withdrawal symptoms after 6 and 12 weeks’ treatment with diazepam or buspirone. British Journal of Psychiatry 154: 529–534, 1989

    Article  PubMed  CAS  Google Scholar 

  • Naranjo CA, Sellers EM, Sullivan JT, Woodley DV, Kadlec K, et al. The serotonin uptake inhibitor catalopram attenuates ethanol intake. Clinical Pharmacological Therapy 41: 266–274, 1987

    Article  CAS  Google Scholar 

  • Naumenko EV, Popova NK, Nikulina EM, Dygalo NN, Shiskina GT, et al. Behavior, adrenocortical activity, and brain monoamines in Norway rats selected for reduced aggressiveness towards man. Pharmacology, Biochemistry and Behavior 33(1): 85–91, 1989

    Article  CAS  Google Scholar 

  • Neppe VM. High-dose buspirone in case of tardive dyskinesia. Lancet 2(8677): 1458, 1989

    Article  PubMed  CAS  Google Scholar 

  • Nyström C, Hällström T. Comparison between a serotonin and a noradrenaline reuptake blocker in the treatment of depressed outpatients: a cross-over study. Acta Psychiatrica Scandinavica 75: 377–382, 1987

    Article  PubMed  Google Scholar 

  • Palfreyman MG, Mir AK, Kubina M, Middlemiss DN, Richards M, et al. Monoamine receptor sensitivity changes following chronic administration of MDL 72394, a site-directed inhibitor of monoamine oxidase. European Journal of Pharmacology 106: 539–546, 1986

    Google Scholar 

  • Pato MT, Pigott TA, Hill JL, Grover G, Bernstein SE, et al. Clomipramine vs buspirone in OCD: a controlled trial. New Research Program and Abstracts of the Annual Meeting of the American Psychiatric Association, p. 34, San Francisco, May 6–11, 1989

  • Pecknold JC, Matas M, Howarth BG, Ross C, Swinson R, et al. Evaluation of buspirone as an antianxiety agent: buspirone and diazepam versus placebo. Canadian Journal of Psychiatry 34: 766–771, 1989

    CAS  Google Scholar 

  • Peričić D, Manev H. Behavioural evidence for simultaneous dual changes of 5-HT receptor subtypes: mode of antidepressant action? Life Sciences 42: 2593–2601, 1988

    Article  PubMed  Google Scholar 

  • Peroutka SJ, Sleight AJ, McCarthy BG, Pierce PA, Schmidt AW, et al. The clinical utility of pharmacological agents that act as serotonin receptors. Journal of Neuropsychiatry 1(3): 253–262, 1989

    CAS  Google Scholar 

  • Peroutka SJ, Snyder SH. Multiple serotonin receptors: differential binding of (3H) serotonin, (3H) lysergic acid diethylamide, and (3H) spiroperidol. Molecular Pharmacology 16: 687–699, 1979

    PubMed  CAS  Google Scholar 

  • Pierce WA, Bielefeld M. Buspirone-induced mania. Journal of Clinical Psychopharmacology 9: 150–151, 1989

    Article  Google Scholar 

  • Pohl R, Balon R, Yeragani VK, Gershon S. Serotonergic anxiolytics in the treatment of panic disorder: a controlled study with buspirone. Psychopathology 22 (Suppl. 1): 60–67, 1989

    Article  PubMed  Google Scholar 

  • Privette TH, Hornsby RI, Myers RD. Buspirone alters alcohol drinking induced in rats by tetrahydropapaveroline injected into brain monoaminergic pathways. Alcohol 5: 147–152, 1988

    Article  PubMed  CAS  Google Scholar 

  • Rakel RE. Long term buspirone therapy for chronic anxiety: a multicenter international study to determine safety. Southern Medical Journal 83(2): 194–198, 1990

    Article  PubMed  CAS  Google Scholar 

  • Ratey JJ, Sovner R, Mikkelsen E, Chmielinski HE. Buspirone therapy for maladaptive behavior and anxiety in developmentally disabled persons. Journal of Clinical Psychiatry 50(10): 382–384, 1989

    PubMed  CAS  Google Scholar 

  • Riblet LA, Taylor DP, Eison MS, Stanton HC. Pharmacology and neurochemistry of buspirone. Journal of Clinical Psychiatry 43: 11–16, 1982

    PubMed  CAS  Google Scholar 

  • Rickels K. Recent advances in anxiolytic therapy. Journal of Clinical Psychiatry 42: 40–44, 1981

    PubMed  CAS  Google Scholar 

  • Rickels K, Weisman K, Norstad N, Singer M, Stoltz D, et al. Buspirone and diazepam in anxiety: a controlled study. Journal of Clinical Psychiatry 43(12): 18–86, 1982

    Google Scholar 

  • Robinson DS, Alms DR, Shrotriya RC, Messina M, Wickramaratne P. Serotonergic anxiolytics and treatment of depression. Psychopathology 22 (Suppl. 1): 27–36, 1989

    Article  PubMed  Google Scholar 

  • Robinson DS, Shrotriya RC, Alms DR, Messina M, Andary J. Treatment of panic disorder: nonbenzodiazepine anxiolytics, including buspirone. Psychopharmacology Bulletin 25(1): 21–26, 1989a

    PubMed  CAS  Google Scholar 

  • Rowan MJ, Anwyl R. Neurophysiological effects of buspirone and ipsapirone in the hippocampus: comparison with 5-hydroxytryptamine. European Journal of Pharmacology 141: 479–483, 1987

    Article  Google Scholar 

  • Sanger DJ, Joly D, Zivkovic B. Behavioral effects of nonbenzodiazepine anxiolytic drugs: a comparison of CGS 9896 and zopiclone with chlordiazepoxide. Journal of Pharmacological and Experimental Therapeutics 232: 831–837, 1985

    CAS  Google Scholar 

  • Sanghera MK, McMillen BA, German DC. Buspirone, a non-benzodiazepine anxiolytic, increases locus coeruleus noradrenergic neuronal activity. European Journal of Pharmacology 86: 107–110, 1983

    Article  Google Scholar 

  • Schatzberg AF, Dessain E, O’Neil P, Katz DL, Cole J. Recent studies on selective serotonergic antidepressants: trazodone, fluoxetine, and fluvoxamine. Journal of Clinical Psychopharmacology 7 (Suppl.): 44S–49S, 1987

    Article  PubMed  CAS  Google Scholar 

  • Schweizer EE, Amsterdam J, Rickels K, Kaplan M, Droba M. Open trial of buspirone in the treatment of major depressive disorder. Psychopharmacology Bulletin 22(1): 183–185, 1986

    PubMed  CAS  Google Scholar 

  • Segal M. Serotonergic innervation of the locus coeruleus from the dorsal raphe and its action on responses to noxious stimuli. Journal of Physiology 286: 401–415, 1979

    PubMed  CAS  Google Scholar 

  • Sheehan DV, Raj AB, Sheehan KH, Soto S. Is buspirone effective for panic disorder? Journal of Clinical Psychopharmacology 10(1): 3–11, 1990

    Article  PubMed  CAS  Google Scholar 

  • Shimizu H, Hirose A, Tatsuno T, Nakamura M, Katsube J. Pharmacological properties of SM-3997: a new anxioselective anxiolytic candidate. Japanese Journal of Pharmacology 45: 493–500, 1987

    Article  PubMed  CAS  Google Scholar 

  • Soubrié P. Reconciling the role of central serotonin neurons in human and animal behavior. Behavioral and Brain Sciences 9: 319–354, 1986

    Article  Google Scholar 

  • Soulairac A, Lambinet H, Aymard N. Action du precurseur de la serotonine, le 5-hydroxy-tryptophane sur la Symptomatologie agressive. Annales Médico-Psychologiques 2: 459–463, 1976

    PubMed  CAS  Google Scholar 

  • Stolz JF, Marsden CA, Middlemiss DN. Effect of chronic antidepressant treatment and subsequent withdrawal on (3H)-5-hydroxytryptamine and (3H)-spiperone binding in rat frontal cortex and serotonin receptor mediated behaviour. Psychopharmacology (Berlin) 80: 150–155, 1983

    Article  CAS  Google Scholar 

  • Taylor DP, Riblet LA, Stanton HC. Dopamine and antianxiety activity. Pharmacology, Biochemistry and Behaviour 17 (Suppl. 1): 25–35, 1982

    Article  CAS  Google Scholar 

  • Thoren P, Asberg M, Cronholm B, Jornestedt L, Traskman L. Clomipramine treatment of obsessive-compulsive disorder: I. A controlled clinical trial. Archives of General Psychiatry 37: 1281–1285, 1980

    Article  PubMed  CAS  Google Scholar 

  • Tollefson GD. Serotonin and alcohol: interrelationships. Psychopathology 22 (Suppl. 1): 37–48, 1989

    Article  PubMed  Google Scholar 

  • Tompkins EC, Clemento AJ, Taylor DP, Perhach JL. Inhibition of aggressive behaviour in rhesus monkeys by buspirone. Research Communications in Psychology and Psychiatric Behavior 5: 337–352, 1980

    CAS  Google Scholar 

  • Tye NC, Everitt BJ, Iversen SD. 5-Hydroxytryptamine and punishment. Nature 268: 741–743, 1977

    Article  PubMed  CAS  Google Scholar 

  • VanderMaelen CP, Wilderman RC. Buspirone, a non-benzodiazepine anxiolytic jdrug, causes inhibition of serotonergic dorsal raphe neurons in the rat brain slice. Abstract. Social Neuroscience 10: 259, 1984a

    Google Scholar 

  • VanderMaelen CP, Wilderman RC. Iontophoretic and systemic administration of the non-benzodiazepine anxiolytic drug buspirone causes inhibition of serotonergic dorsal raphe neurons in rats. Federation Proceedings 43: 947, 1984b

    Google Scholar 

  • Virkkunen M, Nuutila A, Goodwin FK, Linnoila M. Cerebrospinal fluid monoamine metabolite levels in male arsonists. Archives of General Psychiatry 44: 241–247, 1987

    Article  PubMed  CAS  Google Scholar 

  • Volavka J, Neziroglu F, Yaryura-Tobias JA. Clomipramine and imipramine in obsessive-compulsive disorder. Psychiatry Research 14: 83–91, 1985

    Article  Google Scholar 

  • Welner SA, De Montigny C, Desroches J, Desjardins P, Suranyi-Cadotte BE. Autoradiographic quantificiation of serotonin 1A receptors in rat brain following antidepressant drug treatment. Synapse 4: 347–352, 1989

    Article  PubMed  CAS  Google Scholar 

  • Westenberg HG, Den Boer JA. Serotonin-influencing drugs in the treatment of panic disorder. Psychopathology 22 (Suppl. 1): 68–77, 1989

    Article  PubMed  Google Scholar 

  • Wheatley D. Buspirone: multicenter efficacy study. Journal of Clinical Psychiatry 43(12): 92–94, 1982

    PubMed  CAS  Google Scholar 

  • Willner P. Antidepressants and serotonergic neurotransmission: an integrative review. Psychopharmacology (Berlin) 85: 387–404, 1985

    Article  CAS  Google Scholar 

  • Yaryura-Tobias JA, Bhagavan HN. L-tryptophan in obsessivecompulsive disorders. American Journal of Psychiatry 134: 1298–1299, 1977

    PubMed  CAS  Google Scholar 

  • Young SN, Teff KL. Tryptophan availability, 5HT synthesis and 5HT function. Progress in Neuro-Psychopharmacology and Biological Psychiatry 13(3–4): 373–379, 1989

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Wayne State University, Detroit, Michigan, USA

    Debra A. Glitz & Robert Pohl

Authors
  1. Debra A. Glitz
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Robert Pohl
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Glitz, D.A., Pohl, R. 5-HT1A Partial Agonists. Drugs 41, 11–18 (1991). https://doi.org/10.2165/00003495-199141010-00002

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00003495-199141010-00002

Search

Navigation